BOSUTINIB MONOHYDRATE

Bosutinib Monohydrate is an oral tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML). It works by blocking the activity of abnormal proteins that signal cancer cells to multiply, thereby helping to slow down the progression of leukemia.

Indications

- Chronic Myeloid Leukemia (CML) in adults - Particularly used in patients resistant or intolerant to prior therapy

Dosage

- Typical dose: 400 mg orally once daily with food - Dose adjustments may be required based on liver function, side effects, and concomitant medications - Always follow the prescribing physician’s guidance

Contra-Indications

- Known hypersensitivity to Bosutinib or any component of the formulation - Severe liver impairment - Pregnancy and breastfeeding (unless advised by a physician)

Special Precautions

- Monitor liver function tests regularly - Caution in patients with cardiac problems or electrolyte imbalances - Avoid grapefruit and grapefruit juice - Inform doctor of any other medications being taken

Side Effects

- Common: Diarrhea, nausea, vomiting, abdominal pain - Others: Fatigue, rash, fever, muscle pain - Rare but serious: Liver toxicity, severe bleeding, low blood cell counts

Drug Interactions

- Strong CYP3A inhibitors (e.g., ketoconazole) may increase drug levels - CYP3A inducers (e.g., rifampicin) may reduce effectiveness - Use caution with anticoagulants and other cancer therapies